Current stock page

Financial Data

CYTK Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

CYTKCytokinetics, Incorporated

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 2/10
$56.13−$0.03 (−0.05%)

Latest quote

  • Momentum
    28
  • Value
    41
  • Quality
    46
  • Risk resilience
    56
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$47.56M$28.62M$19.36M$17.76M$1.94M$66.77M$1.58M$16.93M
Gross Profit$45.34M$25.89M$16.96M$14.89M$1.94M$66.77M$1.58M$16.93M
Operating Income-$167.09M-$179.17M-$183.62M-$178.37M-$166.76M-$111.51M-$155.63M-$139.04M
Net Income-$190.07M-$198.76M-$206.03M-$183.03M-$306.18M-$134.37M-$161.38M-$150.02M
EPS-$1.37-$1.5-$1.67-$1.49-$2.55-$1.12-$1.36-$1.27
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$124.02M-$159.84M-$145.46M-$142.65M-$107.51M-$128.24M-$131.62M-$65.57M
Capital Expenditure-$700K-$4.33M-$5.93M-$5.64M-$9.35M-$4.15M-$5.66M-$1.29M
Free Cash Flow-$124.72M-$164.17M-$151.39M-$148.29M-$116.86M-$132.38M-$137.28M-$66.86M
Net Cash Provided By Operating Activities-$124.02M-$159.84M-$145.46M-$142.65M-$107.51M-$128.24M-$131.62M-$65.57M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$1.82B$1.92B$1.27B$1.42B$1.44B$1.23B$1.26B$1.4B
Total Debt$1.27B$1.27B$1.29B$1.28B$1.2B$858.06M$791.06M$788.68M
Cash And Cash Equivalents$203.43M$255.27M$129.84M$122.52M$225.47M$74.94M$73.68M$94.86M
Total Liabilities$2.15B$2.1B$2.1B$2.08B$1.96B$1.59B$1.53B$1.54B
Total Stockholders Equity-$321.17M-$173.49M-$826.57M-$659.63M-$521.12M-$368.72M-$266.41M-$135.37M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio————————
P/S ratio68.89———————
Debt To Equity————————
Free Cash Flow Yield-7.62%-5.40%-5.78%-6.97%-6.38%-10.46%-10.17%-7.14%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio————————
P/S ratio68.89———————
Return On Equity————————
Debt To Equity————————

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-9.31x
Pb-24.3x
Revenue Growth Yoy2356.46%
EPS Growth Yoy46.27%
Gross Margin91.00%
Operating Margin-625.15%
ROE157.08%
ROIC-42.48%
Debt To Equity-3.96
FCF Yield-7.53%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$56.13
Volume1.01M
RSI (14)38.17
MACD-2.32
MACD signal-2.08
MACD histogram-0.24
ADX (14)25.72
SMA (50)$64.11
SMA (200)$69.78
ATR (14)$2.69
Historical volatility (annualized)57.05%
Volume (20-day average)1.99M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score56/100
Beta1.01
Annual volatility43.65%
Max Drawdown-38.47%
Sharpe Ratio-0.23
VaR (95%, 1-day)-3.98%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

CYTK Financial Data FAQ

What is Cytokinetics, Incorporated's revenue?

Cytokinetics, Incorporated's revenue is one of the core financial data points for CYTK. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Cytokinetics, Incorporated's revenue growing?

Revenue growth shows whether Cytokinetics, Incorporated is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is CYTK's EPS?

CYTK's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Cytokinetics, Incorporated's net income?

Cytokinetics, Incorporated's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Cytokinetics, Incorporated generate?

Free cash flow shows how much cash Cytokinetics, Incorporated generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Cytokinetics, Incorporated have?

Cash and debt help frame CYTK's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.